Friday June 23rd 2017

A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber’s hereditary optic…

We report the first case of definite neuromyelitis optica (NMO) with a pathogenic mitochondrial DNA (mtDNA) mutation for Leber’s hereditary optic neuropathy (LHON) (G11778A point mutation). A 36-year-old Japanese woman had experienced recurrent neurological symptoms originating from involvements of the optic nerves and spinal cord. She finally lost her bilateral vision, and spastic paraparesis and sensory disturbances below the T6 level remained despite intensive immunotherapies. Brain and spinal magnetic resonance imaging (MRI) revealed T2-high-intensity lesions in the optic nerves and thoracic spinal cord, but no lesions in the brain. A blood examination revealed positivity for both anti-aquaproin-4 antibodies and an LHON mtDNA mutation. (Source: Multiple Sclerosis)

See original article here: 

A case of neuromyelitis optica harboring both anti-aquaporin-4 antibodies and a pathogenic mitochondrial DNA mutation for Leber’s hereditary optic…

Leave a Comment

More from category

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]

MS Society Disappointed with Senate Healthcare Bill
MS Society Disappointed with Senate Healthcare Bill

/About-the-Society/News/HealthcareBill-6-22 [Read More]

Type I interferons could have role in natural improvement of RA during pregnancy
Type I interferons could have role in natural improvement of RA during pregnancy

An international US-Danish team of scientists, led by Damini Jawaheer, Ph.D. at the UCSF Benioff Children's Hospital [Read More]

Shared decision-making essential to optimal treatment and quality of life for patients with MS
Shared decision-making essential to optimal treatment and quality of life for patients with MS

One of the cornerstones of multiple sclerosis treatment is shared decision-making between patients and their doctors [Read More]

UC consortium formed to speed up development of new drugs
UC consortium formed to speed up development of new drugs

For 12 years, UCLA researcher Dennis Slamon pursued a groundbreaking approach to treating breast cancer: Attack the [Read More]